Bioequivalence of saxagliptin/metformin immediate release (IR) fixed-dose combination tablets and single-component saxagliptin and metformin IR tablets in healthy adult subjects

Clinical Drug Investigation

Volumn 33, Issue 5, 2013, Pages 365-374

  Upreti, Vijay V ^a   Keung, Chi Fung ^a   Boulton, David W ^a   Chang, Ming ^a   Li, Li ^b   Tang, Angela ^a   Hsiang, Bonnie C ^a   Quamina Edghill, Donette ^a   Frevert, Ernst U ^a   Lacreta, Frank P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b BMS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; METFORMIN PLUS SAXAGLIPTIN; SAXAGLIPTIN;

ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; MALE; OPEN STUDY; OROPHARYNX PAIN; OTALGIA; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADAMANTANE; ADMINISTRATION, ORAL; ADULT; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FASTING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; NEW JERSEY; POSTPRANDIAL PERIOD; TABLETS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 84877083887     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0075-z     Document Type: Article

References (13)

1. Gallwitz B. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. IDrugs. 2008;11(12):906-17.
2. United States Prescribing Information for Onglyza. http://packageinserts. bms.com/pi/pi-onglyza.pdf. Accessed Dec 2011.
3. Wani JH, John-Kalarickal J, Fonseca VA. Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. Cardiol Clin. 2008;26(4):639-48.
4. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 1998;47(11):1663-70.
5. McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept. 2005;128(2):159-65.
6. United States Prescribing Information for Glucophage/Glucophage XR. http://packageinserts.bms.com/pi/pi-glucophage.pdf. Accessed Jan 2009.
7. Hinke SA, Kuhn-Wache K, Hoffmann T, et al. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun. 2002;291:1302-8.
8. Lenhard JM, Croom DK, Minnick DT. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Commun. 2004;324:92-7.
9. Patel CG, Komoroski BJ, Brenner E, Li L, Boulton DW. No meaningful pharmacokinetic drug-drug interaction between saxagliptin and metformin in healthy subjects. Presented at the American College of Clinical Pharmacy Annual Meeting, Denver; 2007. Abstract 213.
10. Monnier L, Benichou M, Charra-Ebrard S, et al. An overview of the rationale for pharmacological strategies in type 2 diabetes: from the evidence to new perspectives. Diabetes Metab. 2005;31(2):101-9.
11. DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, Chen RS. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32:1649-55.
12. Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11:611-22.
13. Desai DS, Li BV, inventors. Bristol-Myers Squibb Company, assignee. Coated tablet formulation and method. US patent application 0110200672; 2011.